eligibility_summary
Eligible: confirmed nonsquamous, unresectable stage IIIB/IIIC or metastatic stage IV NSCLC (no squamous or small-cell), measurable disease (RECIST 1.1), ECOG 0–1, adequate organs. Prior therapy: no AGA—platinum + PD-(L)1 or relapse ≤6 mo after adjuvant platinum plus PD-(L)1, AGA—≥1 targeted therapy, platinum, ≤1 PD-(L)1. Exclude: life <3 mo, taxane/docetaxel allergy, recent cancer, ILD/pneumonitis, DLCO <50%, ≥G3 lung disease, neuropathy ≥G2, uncontrolled diabetes, prior antimicrotubules or >1 cytotoxic line in advanced, recent RT/systemic therapy, active CNS mets (treated, stable allowed).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06012435 tests two drugs in previously treated nonsquamous NSCLC: 1) Sigvotatug vedotin (SGN-B6A, PF-08046047): an antibody–drug conjugate (ADC). Mechanism: a monoclonal IgG targets integrin β6 (αvβ6) on tumor cells, is internalized, and via a protease-cleavable linker releases the vedotin payload MMAE (a microtubule-disrupting agent). MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptosis, with potential bystander killing. Drug type: targeted ADC with cytotoxic payload. 2) Docetaxel: a taxane chemotherapy. Mechanism: binds β-tubulin, stabilizes microtubules, prevents depolymerization, leading to mitotic arrest and apoptosis. Drug type: cytotoxic antimicrotubule agent. Target cells/pathways: SGN-B6A targets αvβ6-expressing epithelial tumor cells and impacts integrin/TGF-β–associated tumor biology, both drugs act on microtubule/cell-cycle pathways in dividing cancer cells.